Skip to content

Inspection Record

Jazz Pharmaceuticals, Inc. — FDA 483 Findings

US FDAInspected 2015-07-11Published 2024-01-17 3 findingsRegulatory reporting and change controlOther quality system

Inspectors Daniel J. RobertsThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Regulatory reporting and change control

Written procedures have not been developed for the surveillance, receipt, evaluation, and reporting to FDA of post marketing adverse drug experiences.

2Other quality system

Individual ADEs which were not reported to FDA in a post marketing 15-day alert have not been included in a periodic safety report.

3Other quality system

Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.

A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Jazz Pharmaceuticals, Inc. company profile — full historyAll US FDA findings US FDA documents, 2024 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.